Lancet Respiratory Medicine

Journal Title：Lancet Respiratory Medicine

The Lancet Respiratory Medicine delivers comprehensive, clinically-focused coverage on all areas of respiratory medicine and critical care, including but not limited to: COPD, asthma, cystic fibrosis, IPF, pneumonia, influenza, tuberculosis, sarcoidosis, pulmonary hypertension, sleep medicine, respiratory infections, pulmonary vascular disease, lung cancer, tobacco control, thoracic and reconstructive surgery, mesothelioma, and palliative medicine. Continuing in The Lancet's tradition of publishing high-impact content that influences medical practice, each monthly issue of The Lancet Respiratory Medicine contains Original Research, Reviews, Personal Views, Comments, and News.

The Lancet Respiratory Medicine is stringently edited and peer-reviewed to ensure the scientific merit and clinical relevance of its diverse content. Original Research is fast-tracked to publication within 8 weeks of submission (on average) and published Online First on www.thelancet.com before appearing in print.

Now indexed in PubMed, Journal Citation Reports®, and Scopus, the journal accepts submissions of Original Research, Reviews, Personal Views, and Comments. Visit http://ees.elsevier.com/thelancetrm to learn more about our editorial scope and aims and to submit your manuscript.

Gold or Green Open Access is available for research supported by selected funding agencies with whom Elsevier has an agreement. The journal is also freely available to readers in low-to-middle-income countries via the HINARI programme or via IP access at www.thelancet.com.

To find out more about The Lancet Respiratory Medicine, visit www.thelancet.com/respiratory.

《柳叶刀》呼吸内科提供全面的、以临床为中心的覆盖范围，涵盖呼吸内科和重症监护的所有领域，包括但不限于：COPD、哮喘、囊性纤维化、IPF、肺炎、流感、肺结核、结节病、肺动脉高压、睡眠医学、呼吸道感染、肺血管疾病、肺癌、烟草控制、胸外科和重建手术、间皮瘤和姑息治疗。秉承《柳叶刀》出版影响医学实践的高影响力内容的传统，《柳叶刀呼吸医学》的每期月刊都包含原创研究、评论、个人观点、评论和新闻。

《柳叶刀呼吸医学》经过严格编辑和同行评审，以确保其多样化内容的科学价值和临床相关性。原创研究会在提交后 8 周内快速发布（平均），并在印刷前先在 www.thelancet.com 上在线发表。

该期刊现已在 PubMed、Journal Citation Reports® 和 Scopus 中编入索引，接受原始研究、评论、个人观点和评论的提交。访问 http://ees.elsevier.com/thelancetrm 了解更多关于我们的编辑范围和目标并提交您的手稿。

Gold 或 Green Open Access 可用于与 Elsevier 有协议的选定资助机构支持的研究。该期刊还可以通过 HINARI 计划或通过 www.thelancet.com 上的 IP 访问免费提供给中低收入国家的读者。

要了解有关《柳叶刀》呼吸内科的更多信息，请访问 www.thelancet.com/respiratory。

Lancet Respiratory Medicine创刊于2013年，由ELSEVIER SCI LTD出版商出版，收稿方向涵盖RESPIRATORY SYSTEM - RESPIRATORY SYSTEM全领域，在行业领域中学术影响力很大，属于TOP期刊，国际一流期刊，关注度和专业度非常高，所以对原创文章要求创新性很高，过审难度很高，如果您有志于TOP期刊，建议关注此刊。影响因子指数25.094，该期刊近期没有被列入国际期刊预警名单，广大学者值得一试。